To investigate whether PPAR-γ mediated miR-1468-induced biological function in HCC cells, we treated miR-1468-overexpressing Hep3B cells with the agonist rosiglitazone (40 μM). This evidence concerns the gene PPARG and hepatocellular carcinoma.